drugset / Trial / NCT05704361
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary purpose of the study is to evaluate the safety and tolerability of a single-ascending intravenous (IV) dose (Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3) of RO7121932 in participants with multiple sclerosis (MS).
Timeline
- Start
- 2021-08-11
- Primary completion
- 2027-07-08
- Completion
- 2027-07-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RO7121932 | Unknown | 7 mg | Intravenous |
| Subject | RO7121932 | Unknown | 70 mg | Intravenous |
| Subject | RO7121932 | Unknown | 200 mg | Intravenous |
| Subject | RO7121932 | Unknown | 700 mg | Intravenous |
| Subject | RO7121932 | Unknown | 2000 mg | Intravenous |